Cambridge Antibody - Director Shareholding
June 02 2000 - 6:19AM
UK Regulatory
RNS Number:6007L
Cambridge Antibody Tech Group PLC
2 June 2000
Schedule 11 - Notification of interests of Directors and Connected Persons
1 Name of company:
Cambridge Antibody Technology
2 Name of director:
John Aston
3 Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non- beneficial interest:
as in 2
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified):
As in 2
5 Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s):
As in 2
6 Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary:
Allocation of pro-rata entitlement pursuant to open offer to shareholders
7 Number of shares/amount of stock acquired:
362
8 Percentage of issued class:
0.0011%
9 Number of shares/amount of stock disposed:
10 Percentage of issued class:
11 Class of security:
10p ordinary shares
12 Price per share:
1850p
13 Date of transaction:
10 April 2000
14 Date company informed:
10 April 2000
15 Total holding following this notification:
2,489
16 Total percentage holding of issued class following this notification:
0.0073%
If a director has been granted options by the company, please complete the
following fields:
17 Date of grant:
18 Period during which or date on which exercisable:
19 Total amount paid (if any) for grant of the option:
20 Description of shares or debentures involved: class, number:
21 Exercise price (if fixed at time of grant) or indication that price is to
be fixed at time of exercise:
22 Total number of shares or debentures over which options held following
this notification:
23 Contact name for queries:
Diane Mellett
24 Contact telephone number:
01763 263 233
25 Name of company official responsible for making notification:
Diane Mellett
Schedule 11 - Notification of interests of Directors and Connected Persons
1 Name of company:
Cambridge Antibody Technology
2 Name of director:
Peter Garland
3 Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non- beneficial interest:
as in 2
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified):
as in 2
5 Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s):
as in 2
6 Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary:
Allocation of pro-rata entitlement pursuant to open offer to shareholders
7 Number of shares/amount of stock acquired:
270
8 Percentage of issued class:
0.0008%
9 Number of shares/amount of stock disposed:
10 Percentage of issued class:
11 Class of security:
10p ordinary shares
12 Price per share:
1850p
13 Date of transaction:
10 April 2000
14 Date company informed:
10 April 2000
15 Total holding following this notification:
82,006
16 Total percentage holding of issued class following this notification:
0.24%
If a director has been granted options by the company, please complete the
following fields:
17 Date of grant:
18 Period during which or date on which exercisable:
19 Total amount paid (if any) for grant of the option:
20 Description of shares or debentures involved: class, number:
21 Exercise price (if fixed at time of grant) or indication that price is to
be fixed at time of exercise:
22 Total number of shares or debentures over which options held following
this notification:
23 Contact name for queries:
Diane Mellett
24 Contact telephone number:
01763 263233
25 Name of company official responsible for making notification:
Diane Mellett
Schedule 11 - Notification of interests of Directors and Connected Persons
1 Name of company:
Cambridge Antibody Technology
2 Name of director:
Uwe Bicker
3 Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non- beneficial interest:
as in 2
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified):
as in 2
5 Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s):
As in 2
6 Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary:
Allocation of pro-rata entitlement pursuant to open offer to shareholders
7 Number of shares/amount of stock acquired:
246
8 Percentage of issued class:
0.0007%
9 Number of shares/amount of stock disposed:
10 Percentage of issued class:
11 Class of security:
10p ordinary shares
12 Price per share:
1850p
13 Date of transaction:
10 April 2000
14 Date company informed:
10 April 2000
15 Total holding following this notification:
1,988
16 Total percentage holding of issued class following this notification:
0.0058%
If a director has been granted options by the company, please complete the
following fields:
17 Date of grant:
18 Period during which or date on which exercisable:
19 Total amount paid (if any) for grant of the option:
20 Description of shares or debentures involved: class, number:
21 Exercise price (if fixed at time of grant) or indication that price is to
be fixed at time of exercise:
22 Total number of shares or debentures over which options held following
this notification:
23 Contact name for queries:
Diane Mellett
24 Contact telephone number:
01763 263233
25 Name of company official responsible for making notification:
Diane Mellett
Schedule 11 - Notification of interests of Directors and Connected Persons
1 Name of company:
Cambridge Antibody Technology
2 Name of director:
Paul Nicholson
3 Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non- beneficial interest:
as in 2
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified):
as in 2
5 Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s):
As in 2
6 Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary:
Allocation of pro-rata entitlement pursuant to open offer to shareholders
7 Number of shares/amount of stock acquired:
529
8 Percentage of issued class:
0.0015%
9 Number of shares/amount of stock disposed:
10 Percentage of issued class:
11 Class of security:
10p ordinary shares
12 Price per share:
1850p
13 Date of transaction:
10 April 2000
14 Date company informed:
10 April 2000
15 Total holding following this notification:
4,271
16 Total percentage holding of issued class following this notification:
0.012%
If a director has been granted options by the company, please complete the
following fields:
17 Date of grant:
18 Period during which or date on which exercisable:
19 Total amount paid (if any) for grant of the option:
20 Description of shares or debentures involved: class, number:
21 Exercise price (if fixed at time of grant) or indication that price is to
be fixed at time of exercise:
22 Total number of shares or debentures over which options held following
this notification:
23 Contact name for queries:
Diane Mellett
24 Contact telephone number:
01763 263233
25 Name of company official responsible for making notification:
Diane Mellett
Schedule 11 - Notification of interests of Directors and Connected Persons
1 Name of company:
Cambridge Antibody Technology
2 Name of director:
John Stocker
3 Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non- beneficial interest:
As in 2 above
4 Name of registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified):
As in 2 above
5 Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s):
As in 2
6 Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary:
Allocation of pro-rata entitlement pursuant to open offer to shareholders
7 Number of shares/amount of stock acquired:
387
8 Percentage of issued class:
0.0011%
9 Number of shares/amount of stock disposed:
10 Percentage of issued class:
11 Class of security:
10p ordinary shares
12 Price per share:
1850p
13 Date of transaction:
10 April 2000
14 Date company informed:
10 April 2000
15 Total holding following this notification:
3,129
16 Total percentage holding of issued class following this notification:
0.0091%
If a director has been granted options by the company, please complete the
following fields:
17 Date of grant:
18 Period during which or date on which exercisable:
19 Total amount paid (if any) for grant of the option:
20 Description of shares or debentures involved: class, number:
21 Exercise price (if fixed at time of grant) or indication that price is to
be fixed at time of exercise:
22 Total number of shares or debentures over which options held following
this notification:
23 Contact name for queries:
Diane Mellett
24 Contact telephone number:
01763 263233
25 Name of company official responsible for making notification:
Diane Mellett
END
RDSEAFKAEEDEEFE
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Aug 2023 to Aug 2024